Trabectedin is an FDA-approved DNA minor groove binder that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability.
Trabectedin is a DNA minor groove binder (MGB) that was FDAapproved in 2015 after showing an increased median progression-free survival compared to dacarbazine in patients with metastatic or recurrent leiomyosarcoma or liposarcoma. 1 A known myelosuppresive agent, significant neutropenia is a side effect of treatment with trabectedin. 2 A recent study showed that trabectedin induced apoptosis and inhibition of growth of hematopoietic progenitor cells in patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia (CMML). 3 Lurbinectedin (PM01183) is a next-generation minor groove binder structurally similar to trabectedin except for the C subunit, which contains a tetrahydro β-carboline rather than the additional tetrahydroisoquinoline of trabectedin. 4, 5 It has highly potent in vitro and in vivo antitumor activity by covalently modifying guanines in the DNA minor groove, causing DNA double-strand breaks, arrest in the S-phase of mitosis, and cell death by apoptosis. 4 It also exerts an effect on the tumor microenvironment by decreasing tumor-associated macrophages and tumor vasculature. 6 Lurbinectedin inhibits genes of the RhoGTPase pathway (involved in signaling events such as actin-cytoskeleton organization and cell motility) in monocytes and myeloid leukemic cells, and it inhibits myeloid-derived suppressor cells in vitro and in vivo. 6, 7 There have been 4 phase 1 trials with lurbinectedin in solid tumors [8] [9] [10] [11] investigating the recommended dose of lurbinectedin administration with promising results in combination with another agent in small cell lung cancer and soft tissue sarcoma.
To study the safety and clinical activity of lurbinectedin, we performed a 2-institution phase 1 clinical trial in patients with advanced, relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Given the clinical heterogeneity of AML with different responses to therapy based on cytogenetics and other characteristics, we also examined the impact of chromosome abnormalities and prior therapy with hypomethylating agents. CPK increase, prolonged pancytopenia with hypocellular bone marrow >50 days from start of therapy, any nonhematologicla toxicity of grade ≥3 considered unrelated to underlying disease or tumor lysis syndrome, grade ≥3 asthenia, nonclinically relevant isolated biochemical abnormalities, omission of drug administration on 2 days of induction due to AEs suspected to be related to lurbinectedin, and delay in administration of post-induction therapy >2 weeks due to any nonhematological AE suspected to be related to lurbinectedin.
After treatment discontinuation, patients were followed every 4 weeks until resolution of toxicities. Patients who discontinued treatment without progression were followed every 4 weeks for disease status until disease progression, start of other antitumor therapy, death, or the predefined end-of-study date, whichever occurred first.
| Exploratory and statistical analysis
Peripheral blood and bone marrow samples were collected prior to treatment. Patients at MDACC had molecular diagnostics as a part of routine workup that included flow cytometry, karyotyping, and mutation analysis using next-generation sequencing for leukemia-associated genes. Patients were summarized by dose level with descriptive statistics. Response rates were categorized according to criteria corresponding to leukemia subtype, 12 and included morphologic leukemia-free state (MLFS). Responses were characterized using descriptive statistics, and overall response rate included complete (CR), partial responses (PR), and MLFS. Comparison of data was performed using a 2-sided t Table 1 . Overall, using the day 1 and day 8 schedule (n = 24), 3 patients were treated at the 3.5 mg dose level, 4 at 5 mg, 11 at 7 mg, and 6 at 6 mg Among patients on the day 1 to 3 schedule (n = 18), 5 were treated at the 2 mg dose level, 6 at 3 mg, 4 at 1 mg, and 3 at 1.5 mg.
All 24 treated patients on the day 1 and 8 schedule received the induction phase, 3 patients (13%) received the reinduction phase, and 1 patient (4%) received the consolidation phase with a median of 1 phase (range, 1-3 phases). All 18 treated patients on the day 1 to 3 schedule received the induction phase, and 9 patients (50%)
received the reinduction phase with a median of 1 phase (range, 1-3 phases).
| Toxicities
Dose-limiting toxicity was observed at 2 of the dose levels tested and occurred in 3 out of 16 evaluable patients (19%) on the day 1 and 8 schedule ( Table 2) hence, the MTD and RD could not be determined for the schedule of PM01183 as a 1-hour intravenous infusion on days 1 to 3.
| Safety
All 42 treated patients were evaluable for safety. Table 3 summarizes all AEs observed during both schedules. The majority of adverse events included gastrointestinal manifestations (n = 11), febrile neutropenia and infections (n = 4), pulmonary toxicity (n = 2), and renal failure (n = 2). Nausea and/or vomiting (n = 9), diarrhea (n = 2), cellulitis (n = 2), and acute renal failure (n = 2) were the most common toxicities.
Seven of 16 (44%) of the reported AEs on the day 1 and day 8 schedule occurred in the patients who received 7 mg of lurbinectedin, and 13 of 14 (93%) of the reported adverse events on the day 1 to day 3 schedule occurred in the patients who received 3 mg of lurbinectedin. The biochemical and hematological abnormalities observed during both schedules are also delineated, with the most common being an increase in creatinine (93%) and anemia, neutropenia, and thrombocytopenia (100%), respectively.
All 42 patients who received lurbinectedin discontinued treatment prior to the study cutoff. The primary reasons for discontinuation in both schedules were progressive disease (n = 12 for days 1 and 8, n = 11 for days 1 to 3) and death (n = 6 for days 1 and 8, n = 4 for days 1 to 3). There were no treatment delays during the study due to lurbinectedin-related reasons, but 1 patient receiving lurbinectedin from days 1 to 3 had the day 3 infusion delayed by 1 day due to reasons unrelated to treatment.
| Clinical activity and outcomes
Pretreatment and posttreatment data on peripheral and marrow blasts were available for all patients. Out of 42 patients, 33 (79%) experienced reduction in bone marrow blasts and/or peripheral blood blasts at nadir. Twenty-three patients (55% of all patients) had >50% reduction in blast percentage in either the PB or BM, and of these, 5 (12%) had >50% reduction in both PB and BM with lurbinectedin 1 mg (n = 1), 2 mg (n = 1), 5 mg (n = 2), and 7 mg (n = 1).
A total of 34 patients (17 in each dosing schedule) were evaluable for efficacy. At best response, 2 patients (5%) reached a MLFS and 1 patient (2%) experienced PR with a progression-free survival (PFS) of 1.3 to 3.2 months (Table 4) . Most patients (n = 13 in day 1 and 8 schedule, n = 16 in days 1 to 3 schedule) had relapsed or refractory disease.
Early deaths were attributed to disease-related causes, including relapse/progression (n = 7, 17%), sepsis (n = 5, 12%), and cardiopulmonary failure (n = 2, 5%). 
| Exploratory analysis
Twenty patients had bone marrow results analyzable for responses in the context of chromosomal aberrations and prior therapy. Patients with abnormalities at chromosome 11q21-23 (n = 4) had significantly greater bone marrow blast reduction than those without this abnormality (n = 16), with reductions of 31 ± 14% vs 8 ± 8%, respectively (P = .04; Figure 1A ). There was no difference in blast change with respect to exposure to prior hypomethylating agent therapy (P = .78). Among patients with complex cytogenetics, 5 out of 9 (56%) had blast percentage reductions, similar to patients without complex cytogenetics, where 5 out of 11 (45%) had reductions ( Figure 1B) . The number of cytogenetic abnormalities did not correlate with the change in BM blast percentage (P = .45, Figure 1C) , or with the change in absolute PB blasts (P = .12, Adverse events Alkaline phosphatase increase 25 3.5 mg (n = 1), 5 mg (n = 3), 7 mg (n = 4), 6 mg (n = 6), 2 mg (n = 4), 3 mg (n = 4), 1 mg (n = 2), 1.5 mg (n = 1)
AST increase 25 2 1 3.5 mg (n = 3), 5 mg (n = 2), 7 mg (n = 7), 6 mg (n = 5), 2 mg (n = 2), 3 mg (n = 6), 1 mg (n = 2), 1.5 mg (n = 1)
Bilirubin increase 12 5 1 5 mg (n = 1), 7 mg (n = 4), 6 mg (n = 5), 2 mg (n = 1), 3 mg (n = 4), 1 mg (n = 1), 1.5 mg (n = 2) CPK increase 6 4 3.5 mg (n = 1), 5 mg (n = 1), 7 mg (n = 2), 6 mg (n = 4), 3 mg (n = 2)
Creatinine increase 33 6 3.5 mg (n = 3), 5 mg (n = 3), 7 mg (n = 11), 6 mg (n = 5), 2 mg (n = 4), 3 mg (n = 6), 1 mg (n = 3), 1.5 mg (n = 4)
Hematological abnormalities a Anemia 42 3.5 mg (n = 3), 5 mg (n = 4), 7 mg (n = 11), 6 mg (n = 6), 2 mg (n = 5), 3 mg (n = 6), 1 mg (n = 4), 1.5 mg (n = 3) Leukopenia 1 3 36 3.5 mg (n = 3), 5 mg (n = 4), 7 mg (n = 11), 6 mg (n = 5), 2 mg (n = 4), 3 mg (n = 6), 1 mg (n = 4), 1.5 mg (n = 3) Lymphocytosis 5 5 mg (n = 1), 7 mg (n = 1), 6 mg (n = 1), 2 mg (n = 1), 3 mg (n = 1) Lymphopenia 4 11 26 3.5 mg (n = 3), 5 mg (n = 4), 7 mg (n = 11), 6 mg (n = 5), 2 mg (n = 5), 3 mg (n = 6), 1 mg (n = 4), 1.5 mg (n = 3) Neutropenia 1 1 40 3.5 mg (n = 3), 5 mg (n = 4), 7 mg (n = 11), 6 mg (n = 6), 2 mg (n = 5), 3 mg (n = 6), 1 mg (n = 4), 1.5 mg (n = 3) Thrombocytopenia 1 41 3.5 mg (n = 3), 5 mg (n = 4), 7 mg (n = 11), 6 mg (n = 6), 2 mg (n = 5), 3 mg (n = 6), 1 mg (n = 4), 1.5 mg (n = 3)
Data shown are n (%) of patients.
a Based on total patients with laboratory data available. Figure 1D ). No other associations between blast reductions and prior therapy or chromosomal changes were found among these patients.
| DISCUSSION
The phase 1 trial reported here found lurbinectedin to be safe and toler- cytotoxic chemotherapy showed myelosuppression to be the main toxicity with no reports of rhabdomyolysis. [8] [9] [10] [11] In the current study, there were 2 cases of cellulitis and 1 case of febrile neutropenia.
Patients on study had very high-risk AML/MDS characteristics. patients. KMT2A (MLL), located at 11q23, is recurrently disrupted in leukemia, and therapeutic strategies for these subsets are needed. 13 Lurbinectedin has previously been shown to inactivate the EWS-FLI1 transcription factor, associated with t(11;22)(q24;q12) in Ewing's sarcoma, potentially with redistribution of the fusion protein to the nucleolus. 14 Minor groove binders could also have efficacy against cells with specific structurally unstable chromosomal alterations. In a previous study testing tallimustine, also a MGB, 15 
